SCHEDULE 13D: BioCardia Chairman Andrew Blank Boosts Stake to 5.5% Through Recent Private Placement

Andrew Scott Blank, Chairman of BioCardia, Inc.'s Board of Directors, has increased his beneficial ownership in the company to 5.5% following a recent private placement and other share acquisitions.

Summary

• Andrew Scott Blank, the Reporting Person and Chairman of BioCardia, Inc.'s Board of Directors, beneficially owns 278,253 shares of the Issuer's Common Stock.
• This ownership represents 5.5% of the Issuer's outstanding Common Stock, based on 5,094,439 shares outstanding as of April 23, 2025.
• The beneficial ownership includes 2,035 shares held directly by Mr. Blank, 273,734 shares held by the Andy Blank Revocable Living Trust (of which he is trustee), and 2,484 shares subject to stock options exercisable within 60 days of April 23, 2025.
• On April 23, 2025, the Andy Blank Revocable Living Trust purchased 131,233 shares of Common Stock and warrants to purchase an equal number of shares in a private placement for an aggregate price of $250,000.
• The company effected a 1-for-15 reverse stock split of its common stock on May 30, 2024, with all share quantities and per share amounts retroactively adjusted.
• The Reporting Person's past acquisitions include purchases by the Trust in public offerings on August 6, 2019 ($90.00/unit), June 19, 2020 ($31.50/share), December 16, 2022 ($25.20/share), June 23, 2023 ($35.04/share), and September 3, 2024 ($3.00/share and accompanying warrant).
• Mr. Blank also received 2,035 shares from the vesting of restricted stock units between May 8, 2021, and May 8, 2023.
• The Reporting Person holds the shares for investment purposes and may change his intentions regarding future acquisitions or dispositions based on various market and company factors.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. An insider, particularly the Chairman, increasing their stake in the company through a private placement generally signals confidence in the company's prospects. While the document is a factual disclosure, the action it describes is a positive signal.

Positives

• Increased insider ownership by the Chairman of the Board, Andrew Scott Blank, signaling confidence in the company's future.
• The Chairman's continued investment through a recent private placement demonstrates a commitment to the company.
• The Reporting Person is party to a Securities Purchase and Registration Rights Agreement, providing certain registration rights for his shares and warrants, which can facilitate liquidity.

Risks

• The Reporting Person's future investment intentions (acquiring or disposing of shares) are subject to various factors, including the Issuer's financial position and strategic direction, price levels of the Common Stock, conditions in the securities markets, tax conditions, and general economic and industry conditions.

Future Outlook

The Reporting Person holds shares for investment purposes and may, in the future, acquire additional shares or dispose of existing shares based on various factors including the Issuer's financial position, strategic direction, stock price levels, market conditions, and tax considerations.

Management Comments

• "The Reporting Person is Chairman of the Issuer's Board of Directors and was appointed to the Issuer's Board of Directors on October 1, 2019 and, in such capacity, may have influence over the corporate activities of the Issuer."

Industry Context

This filing reflects an insider's increased stake in a biotechnology company, which is a common occurrence in the industry as executives often invest in their own companies. The multiple past offerings and a reverse stock split suggest the company has been actively managing its capital structure, which is not uncommon for development-stage biotech firms.

Corporate Governance

Related Party Transactions

• The Andy Blank Revocable Living Trust, of which Andrew Scott Blank (the Reporting Person and Chairman) serves as trustee, has repeatedly purchased shares and warrants from BioCardia, Inc. in public offerings and a recent private placement.
• Andrew Scott Blank was issued 2,035 shares of Common Stock in connection with the vesting and delivery of restricted stock units granted to him by the Issuer.

Stakeholder Impact

• Shareholders: Increased insider ownership by the Chairman may be viewed positively, signaling confidence. The registration rights agreement could benefit shareholders by ensuring liquidity for certain large holders.
• Company: The private placement provides capital to the company.

Next Steps

• The Issuer filed a Form S-3 registration statement on April 30, 2025, pertaining to the Private Placement Shares and Warrants, which will facilitate their future liquidity.
• The Reporting Person may acquire additional shares or dispose of existing shares in the future, depending on various market and company-specific factors.

Key Dates

Keywords

BioCardia Inc., Andrew Scott Blank, Schedule 13D, Beneficial Ownership, Common Stock, Private Placement, Warrants, Insider Buying, Corporate Governance, SEC Filing